ArticleMaterials (Basel, Switzerland)2020
Recycling of Spent Pot Lining First Cut from Aluminum Smelters by Utilizing the Two-Step Decomposition Characteristics of Dolomite.
Article in Materials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 29 citations in OpenAlex.
- Research on the Process, Energy Consumption and Carbon Emissions of Different Magnesium Refining Processes.Materials (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Spent Pot Lining First Cut (shortened to SPL-1cut) is a solid waste discharged from a primary aluminum electrolytic production process. SPL-1cut is classified as hazardous waste in China because it contains large amounts of soluble sodium fluoride and a tiny amount of cyanide. Most of SPL-1cut is carbon-about 65%-and its calorific value is 22.587 MJ∙kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.